Amgen's Mixed Advisory Committee Votes On Prolia Still Offer A Good Start
This article was originally published in The Pink Sheet Daily
Executive Summary
The Reproductive Health Drugs Advisory Committee backs Prolia's use to treat osteoporosis in postmenopausal women and bone loss in men undergoing hormone ablation therapy for prostate cancer - though not the largest indication of osteoporosis prevention as well as a REMS.